Commonwealth Equity Services LLC Increases Stock Position in Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Commonwealth Equity Services LLC boosted its holdings in Vivos Therapeutics, Inc. (NASDAQ:VVOSFree Report) by 23.8% in the 4th quarter, Holdings Channel reports. The firm owned 26,000 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Commonwealth Equity Services LLC’s holdings in Vivos Therapeutics were worth $112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Cutter & CO Brokerage Inc. acquired a new position in Vivos Therapeutics in the 4th quarter valued at $163,000. 26.35% of the stock is owned by institutional investors.

Vivos Therapeutics Trading Down 7.7 %

Shares of Vivos Therapeutics stock opened at $2.29 on Friday. The company has a fifty day moving average price of $3.32 and a 200 day moving average price of $3.55. Vivos Therapeutics, Inc. has a twelve month low of $1.91 and a twelve month high of $6.28. The stock has a market cap of $13.49 million, a price-to-earnings ratio of -0.40 and a beta of 7.31.

Vivos Therapeutics (NASDAQ:VVOSGet Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.15. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $3.89 million. Vivos Therapeutics had a negative return on equity of 335.04% and a negative net margin of 86.19%. Analysts forecast that Vivos Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Analyst Ratings Changes

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Vivos Therapeutics in a report on Tuesday, April 1st.

Read Our Latest Stock Report on Vivos Therapeutics

About Vivos Therapeutics

(Free Report)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Featured Stories

Want to see what other hedge funds are holding VVOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vivos Therapeutics, Inc. (NASDAQ:VVOSFree Report).

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.